Latest News and Press Releases

WOODCLIFF LAKE, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...

- Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use - WOODCLIFF LAKE, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...

Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...

Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...

WOODCLIFF LAKE, NJ, Aug. 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...

Phase 2b Clinical Trials for Each of the Company’s Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned WOODCLIFF LAKE, NJ, Aug. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...

 Stable topical composition has potential to reduce side effects of orally delivered compositions in treatment of acne and rosacea  WOODCLIFF LAKE, NJ, July 22, 2020 (GLOBE NEWSWIRE) -- via...

- Phase 2b CONTROL study is evaluating TMB-001 (topical isotretinoin) in subtypes of rare genetic keratinization disorder - - Company also advancing Phase 2b clinical trial evaluating TMB-002...

Decades of experience in drug development and finance to support company advancing novel treatments for rare dermatologic diseases Woodcliff Lake, NJ, June 04, 2020 (GLOBE NEWSWIRE) -- via...

Presentation on Tuesday, June 9th at 2:10pm ET WOODCLIFF LAKE, NJ, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...